-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, China Biopharmaceutical (01177.HK) issued an announcement. The national Class 1 innovative drug TQB2102 “HER2 double epitope ADC” independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), announced two clinical data at the 2026 European Society of Medical Oncology (ESMO) annual meeting, and were selected for the conference selected as Proffered Paper (LBA) and Rapid Oral Report (Rapid Oral) respectively.

Zhitongcaijing·10/26/2026 00:25:13
Listen to the news
Zhitong Financial App News, China Biopharmaceutical (01177.HK) issued an announcement. The national Class 1 innovative drug TQB2102 “HER2 double epitope ADC” independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), announced two clinical data at the 2026 European Society of Medical Oncology (ESMO) annual meeting, and were selected for the conference selected as Proffered Paper (LBA) and Rapid Oral Report (Rapid Oral) respectively.